All Bell ceremonies

Barco One Campus

“Knowledge for Growth”

The 12th edition of " Knowledge for Growth " opened at the sound of the Euronext bell. Steven Peters (CFO van Mithra ) and Henk Joos (Managing Director of FlandersBio ) had the honor to kick off the conference dedicated to life sciences , which is with more than 450 companies and participating organizations , one of the largest of its kind in Europe.

“Knowledge for Growth”

The 12th edition of " Knowledge for Growth " opened at the sound of the Euronext bell. Steven Peters (CFO van Mithra ) and Henk Joos (Managing Director of FlandersBio ) had the honor to kick off the conference dedicated to life sciences , which is with more than 450 companies and participating organizations , one of the largest of its kind in Europe.

“Knowledge for Growth”

The 12th edition of " Knowledge for Growth " opened at the sound of the Euronext bell. Steven Peters (CFO van Mithra ) and Henk Joos (Managing Director of FlandersBio ) had the honor to kick off the conference dedicated to life sciences , which is with more than 450 companies and participating organizations , one of the largest of its kind in Europe.

ASIT biotech

First steps of ASIT biotech on Euronext

Euronext Brussels and Paris welcome ASIT Biotech, a Belgian company specialised in the treatment of allergies. Thierry Legon, CEO of ASIT Biotech, rang the opening bell to celebrate the first listing of the company.

ASIT biotech joins a community of 77 life sciences issuers listed on Euronext.

Headquarted in Belgium, ASIT biotech s.a. (formerly known as Biotech Tools) is a clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+™ technology platform. The company was founded in 1997 as a spin-off company of the Université libre de Bruxelles.

ASIT biotech (ticker code: ASIT) raised € 23.5 million in new capital at a final offer price of € 7.00 per share. With a total of 12,756,800 shares admitted on the day of listing, the company has an initial market capitalisation of € 89.3 million.

The proceeds of the IPO will help ASIT biotech to support the preclinical and clinical development of product candidates, to cover general corporate purposes and to accelerate the discovery of new ASIT+™ platform-based product candidates.

Thierry Legon, Chief Executive Officer of ASIT biotech, declared: “After the successful closing of the subscription period, today’s listing marks a further major milestone in ASIT biotech's development and ambition to change the face of the current allergy immunotherapy (AIT) market by overcoming the main drawbacks of the existing AIT treatments. This initial public offering will support the strong momentum established by our achievements and will allow us to bring our gp-ASIT+™ lead product candidate for grass pollen allergy through Phase III, currently underway in Europe, and to move towards a first application for commercialisation in Germany.  The management team and the Board of Directors would like to take this opportunity to thank both private and institutional investors for subscribing in the offer. It indicates a strong confidence in and support for our strategy.”

ASIT biotech

First steps of ASIT biotech on Euronext

Euronext Brussels and Paris welcome ASIT Biotech, a Belgian company specialised in the treatment of allergies. Thierry Legon, CEO of ASIT Biotech, rang the opening bell to celebrate the first listing of the company.

ASIT biotech joins a community of 77 life sciences issuers listed on Euronext.

Headquarted in Belgium, ASIT biotech s.a. (formerly known as Biotech Tools) is a clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+™ technology platform. The company was founded in 1997 as a spin-off company of the Université libre de Bruxelles.

ASIT biotech (ticker code: ASIT) raised € 23.5 million in new capital at a final offer price of € 7.00 per share. With a total of 12,756,800 shares admitted on the day of listing, the company has an initial market capitalisation of € 89.3 million.

The proceeds of the IPO will help ASIT biotech to support the preclinical and clinical development of product candidates, to cover general corporate purposes and to accelerate the discovery of new ASIT+™ platform-based product candidates.

Thierry Legon, Chief Executive Officer of ASIT biotech, declared: “After the successful closing of the subscription period, today’s listing marks a further major milestone in ASIT biotech's development and ambition to change the face of the current allergy immunotherapy (AIT) market by overcoming the main drawbacks of the existing AIT treatments. This initial public offering will support the strong momentum established by our achievements and will allow us to bring our gp-ASIT+™ lead product candidate for grass pollen allergy through Phase III, currently underway in Europe, and to move towards a first application for commercialisation in Germany.  The management team and the Board of Directors would like to take this opportunity to thank both private and institutional investors for subscribing in the offer. It indicates a strong confidence in and support for our strategy.”

ASIT biotech

First steps of ASIT biotech on Euronext

Euronext Brussels and Paris welcome ASIT Biotech, a Belgian company specialised in the treatment of allergies. Thierry Legon, CEO of ASIT Biotech, rang the opening bell to celebrate the first listing of the company.

ASIT biotech joins a community of 77 life sciences issuers listed on Euronext.

Headquarted in Belgium, ASIT biotech s.a. (formerly known as Biotech Tools) is a clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+™ technology platform. The company was founded in 1997 as a spin-off company of the Université libre de Bruxelles.

ASIT biotech (ticker code: ASIT) raised € 23.5 million in new capital at a final offer price of € 7.00 per share. With a total of 12,756,800 shares admitted on the day of listing, the company has an initial market capitalisation of € 89.3 million.

The proceeds of the IPO will help ASIT biotech to support the preclinical and clinical development of product candidates, to cover general corporate purposes and to accelerate the discovery of new ASIT+™ platform-based product candidates.

Thierry Legon, Chief Executive Officer of ASIT biotech, declared: “After the successful closing of the subscription period, today’s listing marks a further major milestone in ASIT biotech's development and ambition to change the face of the current allergy immunotherapy (AIT) market by overcoming the main drawbacks of the existing AIT treatments. This initial public offering will support the strong momentum established by our achievements and will allow us to bring our gp-ASIT+™ lead product candidate for grass pollen allergy through Phase III, currently underway in Europe, and to move towards a first application for commercialisation in Germany.  The management team and the Board of Directors would like to take this opportunity to thank both private and institutional investors for subscribing in the offer. It indicates a strong confidence in and support for our strategy.”

Mobistar becomes Orange

Mobistar is no more. Long live Orange! It is with new colours that the members of the Board of Mobistar have opened the markets to celebrate the rebranding of the telecom operator as well as the first listing of the new ticker OBEL;

This change will allow the company to boost its processing and support its strategic development through new services. The introduction of the Orange brand will enable Mobistar to strengthen its position on the Belgian market, as convergent operator as well as mobile.

Want to know more? www.orange.be

Mobistar becomes Orange

Mobistar is no more. Long live Orange! It is with new colours that the members of the Board of Mobistar have opened the markets to celebrate the rebranding of the telecom operator as well as the first listing of the new ticker OBEL;

This change will allow the company to boost its processing and support its strategic development through new services. The introduction of the Orange brand will enable Mobistar to strengthen its position on the Belgian market, as convergent operator as well as mobile.

Want to know more? www.orange.be

Mobistar becomes Orange

Mobistar is no more. Long live Orange! It is with new colours that the members of the Board of Mobistar have opened the markets to celebrate the rebranding of the telecom operator as well as the first listing of the new ticker OBEL;

This change will allow the company to boost its processing and support its strategic development through new services. The introduction of the Orange brand will enable Mobistar to strengthen its position on the Belgian market, as convergent operator as well as mobile.

Want to know more? www.orange.be

Agfa Gevaert in TECH40

Agfa Gevaert new entry in TECH40

EnterNext presents a new selection of the TECH40 label of the year 2016. The TECH40 covers the 40 leading, small and mid cap Tech companies listed on Euronext’s markets. These 40 companies were drawn up from the total of 320 listed Tech companies (digital companies, life sciences and eco-industry). A nine-member committee then made the final selection using qualitative and quantitative criteria.  This year, Agfa Gevaert is part if this selection and joins other Belgian companies  such as Ablynx, Barco, Celyad, Econocom, EVS and Zenitel

To consult the complete list of the TECH40 label composition: tech.euronext.com/en/our-tech-companies/tech-40-label

Agfa Gevaert in TECH40

Agfa Gevaert new entry in TECH40

EnterNext presents a new selection of the TECH40 label of the year 2016. The TECH40 covers the 40 leading, small and mid cap Tech companies listed on Euronext’s markets. These 40 companies were drawn up from the total of 320 listed Tech companies (digital companies, life sciences and eco-industry). A nine-member committee then made the final selection using qualitative and quantitative criteria.  This year, Agfa Gevaert is part if this selection and joins other Belgian companies  such as Ablynx, Barco, Celyad, Econocom, EVS and Zenitel

To consult the complete list of the TECH40 label composition: tech.euronext.com/en/our-tech-companies/tech-40-label

Agfa Gevaert in TECH40

Agfa Gevaert new entry in TECH40

EnterNext presents a new selection of the TECH40 label of the year 2016. The TECH40 covers the 40 leading, small and mid cap Tech companies listed on Euronext’s markets. These 40 companies were drawn up from the total of 320 listed Tech companies (digital companies, life sciences and eco-industry). A nine-member committee then made the final selection using qualitative and quantitative criteria.  This year, Agfa Gevaert is part if this selection and joins other Belgian companies  such as Ablynx, Barco, Celyad, Econocom, EVS and Zenitel

To consult the complete list of the TECH40 label composition: tech.euronext.com/en/our-tech-companies/tech-40-label

Double listing anniversary KBC

Together, KBC and KBC Ancora write 80 years of stock market history

Today Euronext celebrated a double listing anniversary: that of bank-insurer KBC and its reference shareholder KBC Ancora. They are listed respectively 65 and 15 years on the Euronext markets. On this occasion, Johan Thijs, CEO of KBC Group, and Franky Depickere, CEO of KBC Ancora, opened the financial markets by ringing the bell.

It's 65 years ago that Kredietbank shares were first listed at the then Brussels Stock Exchange. Since the KBC merger in 1998, the shares have been listed under the KBC label.

Since 2001, following the establishment of Almancora by KBC shareholder Cera, that share has also been listed on Euronext,
first as Almancora and later as KBC Ancora. And so it is that, today, KBC and KBC Ancora have chalked up 80 years of stock market history. Over that period, the two institutions have actively contributed to the development of Belgium's economy and society. Today, Johan Thijs, CEO of KBC Group, and Franky Depickere, Managing Director of KBC Ancora, therefore had the pleasure of being invited to ring the bell to start trading at Euronext Brussels.

Johan Thijs looks to the future: 'In the past 18 years, KBC has grown to become an important, visible market  player  that  is  actively  followed  by  both  individual  investors  and  large  institutional  investors, both  at  home  and  abroad.  In  spite  of  the  sometimes  turbulent market  environment,  KBC's  unique integrated bank-insurance model has proved itself as a foundation for sustainable, profitable growth. With  the  support  of  our  core  shareholders,  we  can  confidently  work  on  rolling  out  our  long-term strategy in the interests of our clients, employees, shareholders and other stakeholders.'

Franky Depickere adds: 'Together with Cera and the other core shareholders, KBC Ancora constitutes a shareholder structure for KBC Group that is stable and rooted in the local community as a basis for healthy onward development and the creation of shareholder value in the long term.'

For more information:
www.kbc.com
www.kbcancora.be

25 years BEL20

Our national blue chip the BEL 20 was created 25 years ago on 18 March.It is based on the performance of the 20 most representative companies for the Belgian market. It first saw the light in 1991 and experienced many changes, both in composition and regulations. To make sure this anniversary did not go unnoticed, Euronext organized a breakfast with CEOs and board members of the 20 constituents of the BEL 20. Deputy Prime Minister Alexander De Croo rang the opening bell.

To know more about the BEL 20, check our dedicated pages :
www.euronext.com/25bel20

25 years BEL20

Our national blue chip the BEL 20 was created 25 years ago on 18 March.It is based on the performance of the 20 most representative companies for the Belgian market. It first saw the light in 1991 and experienced many changes, both in composition and regulations. To make sure this anniversary did not go unnoticed, Euronext organized a breakfast with CEOs and board members of the 20 constituents of the BEL 20. Deputy Prime Minister Alexander De Croo rang the opening bell.

To know more about the BEL 20, check our dedicated pages :
www.euronext.com/25bel20

25 years BEL20

Our national blue chip the BEL 20 was created 25 years ago on 18 March.It is based on the performance of the 20 most representative companies for the Belgian market. It first saw the light in 1991 and experienced many changes, both in composition and regulations. To make sure this anniversary did not go unnoticed, Euronext organized a breakfast with CEOs and board members of the 20 constituents of the BEL 20. Deputy Prime Minister Alexander De Croo rang the opening bell.

To know more about the BEL 20, check our dedicated pages :
www.euronext.com/25bel20

Global Money Week

Kick-off of the Global Money Week at Euronext Brussels

The Global Money Week that starts on 14 March is organised by Wikfin.be, De Tijd, L’Echo and Radio1 and many other partner a.o Euronext. This week aims at stimulating financial education and takes financial questions under the microscope. All lot of activities are organized in schools and info Markets in different cities, as well as for the general public. Minister of Budget, Sophie Wilmès opened the financial markets to celebrate this events in the presence of Minister of Finance, Johan Van Overtveldt and Deputy Prime Minister and Minister of Economy Kris Peeters and the Governer of the National Bank of Belgium and Jean-Paul Servais, Chairman of the FSMA.

Want to find out more : www.deweekvanhetgeld.be
                                           www.lasemainedelargent.be     

Twitter:  #dwvhg16.
               #lsdla16.